Danaher Corporation
DHR · Price history
Price at last available close
$232.09
+$4.76 (+2.09%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Danaher Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 5, 2026. A research update is not a new financial filing.
Who they are
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development.
How they make money
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services. The company operates through three segments—Biotechnology, Life Sciences, and Diagnostics—providing equipment, consumables, software, and services to biopharmaceutical, diagnostic, and research customers.
Products & services
The company provides life sciences research instruments, biopharmaceutical drug production equipment, genomic medicines, protein consumables, and medical diagnostic products and services.
Brands & revenue mix
A key operating company within the Biotechnology segment.
Separate brand revenue is not available in this research.Source
Operating company focused on life sciences instrumentation and platforms.
Separate brand revenue is not available in this research.Source
Operating company specializing in custom nucleic acid products.
Separate brand revenue is not available in this research.Source
Operating company focused on biotechnology and genomic medicine solutions.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company does not disclose any single customer representing 10% or more of its total consolidated revenues for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- supplier_category — The company relies on various third-party suppliers for raw materials, components, and contract manufacturing services, though specific supplier names are not disclosed.Source
Competitors
- Thermo Fisher Scientific — Competes across life sciences, diagnostics, and laboratory equipment markets.Source
- Agilent Technologies — Competes in life sciences and diagnostics instrumentation and software.Source
- Roche Diagnostics — Competes in the medical diagnostics and clinical laboratory testing market.Source
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-26.
Total debt increased 43.1% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
33
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
61
Fair
Financial Strength
72
Business Quality / Moat
35
Management
79
Growth Quality
36
Risk / Durability
93
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
37
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •M&A headline · Oct 18, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for DHR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can DHR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is DHR's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is DHR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify DHR's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of DHR's score?
Essential Investment Snapshot
Wall Street Score
33
Opportunity Score
37
Market Cap
$163.16B
P/E Ratio
39.6
EPS
$5.65
52-Week High
$242.80
52-Week Low
$160.93
Beta
0.80
Intrinsic Value
$48.02
Analyst Target
$240.00
Shares Outstanding
711.0M
Total Revenue
$25.11B
Total Debt
$26.56B
Dividend Yield (TTM)
0.65%
Liquidation Value / Share
$73.95
Dividend / Share (TTM)
$1.52
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for DHR
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Oct 18, 2026
15,838 Shares of Danaher Corporation $DHR Acquired by CWS Financial Advisors LLC — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on DHR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Danaher Business System (DBS).
- +Strong brand names and innovative technologies.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Data privacy and security laws (e.g., GDPR, HIPAA).
- −Risks associated with AI integration and intellectual property.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
8 historical score records availablePrevious Score
33
Oct 20, 2026
Change
Unchanged
Current Score
33
Oct 21, 2026
Category Changes
DHR score was unchanged.
Projected Score
Projected Score
41
Projected Change
+7.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 7.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$232.09
Model Intrinsic Value
$48.02
Difference
+$184.06
+383.3% vs IV
Margin of Safety
-383.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.11B | $24.57B | $23.88B | $23.89B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $10.42B | $9.60B | $9.67B | $9.86B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $14.69B | $14.97B | $14.21B | $14.03B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $1.61B | $1.60B | $1.58B | $1.50B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.95B | $8.23B | $7.44B | $7.25B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $9.56B | $9.83B | $9.02B | $8.76B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $7.58B | $6.95B | $7.28B | $7.50B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $5.13B | $5.14B | $5.18B | $5.28B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $78.0M | $265.0M | $278.0M | $289.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $4.76B | $4.23B | $4.65B | $5.04B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $758.0M | $619.0M | $747.0M | $823.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $4.00B | $3.61B | $3.90B | $4.76B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $5.65 | $5.07 | $5.33 | $6.44 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 705M | 707M | 731M | 737M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 708M | 711M | 737M | 743M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$6.26B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$1.23
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+43.1%
Cash Change
+47.0%
Margin Change
+4.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.5%. EPS increased 59.7%. Cash increased 47.0%. Total debt increased 43.1%. Net income margin improved by 4.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
67
Smart Money
67
Number of Gurus
11
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
8 historical recordsHistorical Score Chart
3 of 8 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Danaher Corporation $DHR Shares Sold by Compass Wealth Management LLC
Danaher Q3 Earnings Call Highlights
Danaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates
Rumor Mill · DHR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial